Novel Immune-Based Therapies for Life-Limiting Diseases NovaBiotics develops immune based therapies for life-threatening and life-limiting diseases. The novel therapies NovaBiotics is developing serve immunocompromised patients who are susceptible to fungal and bacterial infections and also patients with complex, inflammatory-infectious disease of the airways and other tissues and organs. NovaBiotics has generated two proprietary immunotherapy platforms (a peptide and small molecule platform) and the high value...
Addressing the Global Challenge of Alzheimer’s Disease TauRx’s mission is to discover, develop and commercialise innovative products for the diagnosis, treatment, and cure of neurodegenerative diseases such as Alzheimer’s disease (AD) caused through protein aggregation. Dementia is the world’s greatest unmet medical need. As the world’s population ages, the prevalence of AD, the most common form of dementia, is predicted to reach epidemic proportions. Our...
New Drug Development for the treatment of Cancer and Autoimmune Diseases Medannex is developing a new drug (MDX-124) to treat a range of cancers and autoimmune diseases. These conditions affect millions of people worldwide and they are usually debilitating and often life-threatening. Since patients frequently become resistant to existing treatments, there remains an urgent need for novel therapies like ours. Our goal is to help...